Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select.

Literature DB >> 27458310

Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select.

Charles G Drake¹, Trinity J Bivalacqua², Noah M Hahn².

Abstract

Entities: Disease

Mesh：

Substances：
B7-H1 Antigen

Year: 2016 PMID： 27458310 DOI： 10.1200/JCO.2016.68.4696

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

Review 1. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors: Kenneth M Felsenstein; Dan Theodorescu
Journal: Nat Rev Urol Date: 2017-11-14 Impact factor: 14.432

2. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.

Authors: Yanchun Li; Mateusz Opyrchal; Song Yao; Xuan Peng; Li Yan; Hossam Jabbour; Thaer Khoury
Journal: Breast Cancer Res Treat Date: 2018-03-09 Impact factor: 4.872

3. Simple and Efficient Stratification of Invasive Bladder Cancer Patients.

Authors: Jerome Zoidakis
Journal: EBioMedicine Date: 2016-08-28 Impact factor: 8.143

4. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.

Authors: Shenying Jin; Bo Xu; Lixia Yu; Yao Fu; Hongyan Wu; Xiangshan Fan; Jia Wei; Baorui Liu
Journal: Oncotarget Date: 2017-06-13

5. Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.

Authors: Ana M Contreras-Sandoval; María Merino; Marcos Vasquez; Iñaki F Trocóniz; Pedro Berraondo; María J Garrido
Journal: Oncotarget Date: 2016-11-22

Review 6. Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.

Authors: Fabio Pagni; Elena Guerini-Rocco; Anne Maria Schultheis; Giulia Grazia; Erika Rijavec; Michele Ghidini; Gianluca Lopez; Konstantinos Venetis; Giorgio Alberto Croci; Umberto Malapelle; Nicola Fusco
Journal: Int J Mol Sci Date: 2019-11-01 Impact factor: 5.923

Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select.

Review 1. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

2. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.

3. Simple and Efficient Stratification of Invasive Bladder Cancer Patients.

4. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.

5. Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.

Review 6. Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.

Review 7. Current status and future perspectives of immunotherapy in bladder cancer treatment.

Review 8. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.

Review 9. Biomarkers for immunotherapy in bladder cancer: a moving target.

Review 10. Immune checkpoint inhibitors for urothelial carcinoma.